Skip to main navigation
Skip to main content
Skip to Footer

Navigate Novartis

Coronavirus

Global
- Novartis site directory

Our Company
Our Focus
Our Impact
Our Science
Careers

All News

Advanced Search Basic Search

From Date:

To Date:

Show:

All

Featured News

Media Releases

In the News

Stories

Statements

Pulse Updates

Filter By

Language:

En

Fr

De

2021

June

Media Release / Jun 18, 2021

New Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline

Media Release / Jun 11, 2021

Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria

Media Release / Jun 07, 2021

Novartis announces new interim analysis Phase II data for iptacopan in rare kidney disease C3 glomerulopathy (C3G)

Media Release / Jun 06, 2021

Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)

Media Release / Jun 04, 2021

Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Media Release / Jun 04, 2021

Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Media Release / Jun 03, 2021

Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera

Media Release / Jun 03, 2021

Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study

Media Release / Jun 02, 2021

Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma

Media Release / Jun 02, 2021

Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients

Search Results Navigation

Current page 1 of 5
Page 2 of 5
Page 3 of 5
Page 4 of 5
Page 5 of 5
…
Next page
Last page

Related Links

Stay Up-to-Date
We are inspiring our people
Malaria
Novartis SEC Filings

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.

You are here

Home ›
Media

Novartis Global

Navigate Novartis
Contact Us
About Novartis
Our Portfolio
- Global Product Portfolio
- Global Clinical Pipeline
Careers
- Career Search

Connect with Novartis

twitter
linkedin
youtube
facebook
instagram

Novartis Site Directory

© 2021 Novartis AG

Terms of Use
Privacy Policy
Contact Us
Site Map
Cookie Settings

This site is intended for a global audience.